GlassScriptPhysician profile
Steven Robert Punzell
NPI 1437505203
$2,187.74
in general payments reported to CMS, 2019-2025
21 companies · $788 in 2025
The $788 reported for 2025 was more than what 85% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $85.29 · 2021: $376 · 2022: $391 · 2023: $158 · 2024: $389 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $596.24 | 2021-2024 | Senza |
| Medtronic, INC. | $261.34 | 2022-2025 | Inceptiv |
| Collegium Pharmaceutical, INC. | $190.24 | 2021-2025 | Belbuca |
| Globus Medical, INC. | $183.79 | 2025 | Senza |
| Abbott Laboratories | $171.07 | 2021-2025 | Eterna |
| Forte Bio-Pharma LLC | $159.54 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.10 | 2021-2022 | |
| Boston Scientific Corporation | $85.29 | 2020 | |
| Abbvie INC. | $80.01 | 2021-2025 | |
| Vertex Pharmaceuticals Incorporated | $54.98 | 2025 | |
| Curonix LLC | $47.15 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $42.99 | 2021-2023 | Ztlido |
| Almatica Pharma LLC | $40.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $35.49 | 2022-2025 | Ajovy |
| Uswm, LLC | $33.94 | 2023 | Lucemyra, Zimhi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $26.63 | 2025 | Generator |
| Averitas Pharma INC. | $22.71 | 2023 | Qutenza |
| Grt US Holding, INC. | $17.75 | 2022 | |
| Tersera Therapeutics LLC | $16.70 | 2021 | |
| Nalu Medical, INC. | $16.05 | 2021 | |
| Lilly USA, LLC | $14.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Punzell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.